CARTemis Therapeutics

Executive Summary

CARTemis Therapeutics is a German biotechnology company founded in 2019 and based in Munich, specializing in the development of novel CAR-T cell therapies for cancer treatment. The company leverages advanced engineering approaches to enhance the efficacy and safety of CAR-T cells, aiming to overcome current limitations such as antigen escape, tumor microenvironment suppression, and on-target off-tumor toxicity. CARTemis focuses on translating innovative immunotherapies from preclinical research into clinical applications, with a particular emphasis on solid tumors. While still in the early stages of development and lacking publicly disclosed pipeline programs, the company's unique platform technology positions it within the competitive cell and gene therapy landscape. As a private entity with no disclosed funding rounds or valuation, CARTemis represents an early-stage investment opportunity with significant upside potential but correspondingly high technical and clinical risks.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead CAR-T Program30% success
• Q2 2027IND Filing for First-In-Human Clinical Trial20% success
• Q3 2026Series A Financing Round Completion40% success